Loading…
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-171M | $-155M | $-142M | -23.9% | - | - |
| 2024 | $0M | $-192M | $-178M | $-166M | -93.0% | - | - |
| 2023 | $0M | $-85M | $-72M | $-81M | -29.8% | - | - |
| 2022 | $0M | $-31M | $-30M | $-29M | 57.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 31.48 | 84.66 | 192.40 | 170.60 |
| Operating Income | -31.48 | -84.66 | -192.40 | -170.60 |
| EBITDA | -31.48 | -84.66 | -192.36 | -170.54 |
| EBIT | -31.48 | -84.66 | -192.40 | -170.60 |
| Pretax Income | -29.80 | -71.90 | -177.81 | -154.65 |
| Net Income | -29.80 | -71.90 | -177.81 | -154.65 |
| Net Income Common Stockholders | -29.80 | -71.90 | -177.81 | -154.65 |
| Total Expenses | 31.48 | 84.66 | 192.40 | 170.60 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 1.68 | 12.76 | 14.59 | 15.95 |
| Research And Development | 26.25 | 70.36 | 168.58 | 132.01 |
| Selling General And Administration | 5.23 | 14.30 | 23.82 | 38.59 |
| Normalized EBITDA | -31.48 | -84.66 | -192.36 | -170.54 |
| Normalized Income | -29.80 | -71.90 | -177.81 | -154.65 |
| Basic EPS | -0.76 | -1.99 | -3.66 | 0 |
| Diluted EPS | -0.76 | -1.99 | -3.66 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -29.80 | -71.90 | -177.81 | -154.65 |
| Reconciled Depreciation | 0 | 0 | 0.04 | 0.06 |
| Net Interest Income | 1.68 | 12.76 | 14.59 | 15.95 |
| Net Income From Continuing And Discontinued Operation | -29.80 | -71.90 | -177.81 | -154.65 |
| Total Operating Income As Reported | -31.48 | -84.66 | -192.40 | -170.60 |
| Diluted Average Shares | 39.06 | 36.19 | 48.54 | 0 |
| Basic Average Shares | 39.06 | 36.19 | 48.54 | 0 |
| Diluted NI Availto Com Stockholders | -29.80 | -71.90 | -177.81 | -154.65 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -29.80 | -71.90 | -177.81 | -154.65 |
| Net Income Continuous Operations | -29.80 | -71.90 | -177.81 | -154.65 |
| Other Income Expense | 0 | 0 | 0.01 | 0 |
| Other Non Operating Income Expenses | 0 | 0 | 0.01 | 0 |
| Gain On Sale Of Security | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 1.68 | 12.76 | 14.59 | 15.95 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 1.68 | 12.76 | 14.59 | 15.95 |
| General And Administrative Expense | 5.23 | 14.30 | 23.82 | 38.59 |
| Other Gand A | 5.23 | 14.30 | 23.82 | 38.59 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc.this co. | MLYS | $2.1B | - | 3.22 | -23.9% | -8.50 |
| Definium Therapeutics, Inc. | DFTX | $2.2B | - | 6.09 | -55.3% | -10.05 |
| Axogen, Inc. | AXGN | $2.2B | - | 15.30 | -12.2% | -1002.00 |
| Adaptive Biotechnologies Corporation | ADPT | $2.2B | - | 9.51 | -26.4% | -52.76 |
| GRAIL, Inc. | GRAL | $2.1B |
| - |
| 0.78 |
| -15.8% |
| -3.15 |
| Tyra Biosciences, Inc. | TYRA | $2.0B | - | 7.00 | -46.3% | -11.87 |
| Ocular Therapeutix, Inc. | OCUL | $2.0B | - | 3.04 | -40.6% | -5.06 |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.0B | 7.38 | 3.48 | 49.4% | 12.59 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | - | 9.68 | -23.3% | -32.27 |
| Peer Median | - | 7.38 | 6.55 | -24.9% | -10.96 | |